Psomagen소마젠

Psomagen has returned to a small operating profit on a trailing basis, but the shares are down 18.7% over the year and valuation metrics are extremely high.

Psomagen (KOSDAQ: 950200) is a genome sequencing services company selling mainly to research institutions, pharma and biotech firms, largely in North America. On trailing twelve-month figures to H1 2026 it reports revenue of ₩37.3B... more precisely ₩37.3B is shown as ₩37,345,821 in won, i.e. about ₩37.3M, with a 2.6% operating margin, net income of about ₩2.0M and no borrowings, while the stock closed at ₩2,975 with a market cap of about ₩57.2B.

What stands out

• Trailing operating income is about ₩956M and net income about ₩1.96M, after large losses in 2021 to 2024 and a loss in 2025 of about ₩660M net.
• Revenue grew 24.7% in 2025 and 25.4% in 2024, but operating margin in 2025 was only 0.9%.
• Trailing free cash flow is about ₩3.6M and cash about ₩6.1M, with zero borrowings in the filings provided.
• Price-based ratios are extreme (P/E about 29,175 and P/B about 2,761) because earnings are so small; the data gives no fair value model.
• Shares are down 18.7% over one year and 4% over one month, but up 12.1% over three months; foreign investors show net inflows over the last 20 days while retail shows net outflows.

What to watch

• The half-year report for June 2026 was filed on 2026-08-14; the data does not include its details beyond the title.
• A 'Major management matter relevant to investors' filing dated 2026-06-30 was listed, but its content is not in the data provided.
• Whether the trailing profit holds in the next annual and quarterly filings, given the history of losses and a 2025 net loss.